⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Mitsubishi Tanabe Pharma Corporation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Mitsubishi Tanabe Pharma Corporation (MTPC) is a historic Japanese pharmaceutical company founded in 1678, headquartered in Osaka. The company focuses on creating innovative medicines for serious and life-threatening illnesses, with core therapeutic areas including central nervous system (CNS) disorders, immuno-inflammation, diabetes, and kidney diseases.
In 2025, the company transitioned to an independent entity following its acquisition by the private equity firm Bain Capital from the Mitsubishi Chemical Group. This shift is aimed at accelerating R&D productivity, enhancing commercialization, and fostering growth through strategic investments and partnerships.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CNS therapeutics, Immuno-inflammation, Diabetes
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$2B-$3B
Founded:1678
Ownership:private
Status:operating
FUNDING
Investors:Bain Capital
PIPELINE
Stage:Phase 3
Lead Drug Stage:Filed
Modalities:Small molecule, Monoclonal antibody
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Bain Capital
Acquired By:Bain Capital (2025-01-01)
Subsidiaries:Tanabe Pharma Canada, Tanabe Pharma America
Key Partnerships:Amgen (Inebilizumab), Minerva Neurosciences (Roluperidone), GARDP (Compound library access), GV20 Therapeutics (ADC collaboration)
COMPETITION
Position:Leader
Competitors:Takeda Pharmaceutical, Daiichi Sankyo, Eisai, Shionogi
LEADERSHIP
Key Executives:
Akihisa Harada - CEO
Akihiro Tsujimura - COO
Board Members:Costa Saroukos, Ryousuke Tanabe, Yuji Sugimoto
LINKS
Website:mm.mt-pharma.co.jp
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Mitsubishi Tanabe Pharma Corporation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.